NCT04152096View on ClinicalTrials.gov

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns

PHASE4CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

May 12, 2021

Conditions
BurnsIntoxication
Interventions
DRUG

Rheosorbilact®

Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.

DRUG

Ringer lactate

Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.

Trial Locations (5)

Unknown

Karaganda State Medical University; Regional Center of Traumatology and Orthopedics named after Professor H.Zh.Makazhanov, Karaganda

Republic Clinical Hospital of Traumatology and Orthopedy, Chisinau

Kyiv City Clinical Hospital №2; Shupyk National Medical Academy of Postgraduate Education, Kyiv

Vinnytska Pyrohov's State Clinical Hospital, Vinnytsia

Republic Scientific Center of Ambulance, Tashkent

All Listed Sponsors
lead

Yuria-Pharm

INDUSTRY

NCT04152096 - Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns | Biotech Hunter | Biotech Hunter